Coronary vasodilator reserve in untreated and treated hypertensove patients with and without left ventricular hypertrophy  by Antony, Isabelle et al.
514
Coronary Vasodilator Reserve in Untreated and Treated Hypertensive
Patients With and Without Left Ventricular Hypertrophy
ISABELLE ANTONY, MD, ALAIN NITENBERG, MD, JEAN-MARC FOULT, MD,
EDUARDO APTECAR, MD
Paris, France
Ofrcaves
. This study was Initiated to compare the coronary
reserve In treat hypertensive patients with and
without left
ventricular hypertrophy with that in untreated patients
.
Background. Coronary reserve Is Impaired in hypertensive
patients with left ventricular hypertrophy and normal coronary
arteries . Moreover, basal coronary resistance Is elevated
ht by
pertetulve patients without left ventricular hypertrophy
.
Methods. Coronary reserve was measured with a coronary
Doppler catheter before and after a maximally mWilating dose
of lntracoronary papaverine (peaklrest flow velocity ratio) In
16
control subjects and 37 hypertensive patients with normal epicar-
dial coronary arteries
. Among 20 untreated hypertensive patients,
myocardial mass was Increased in 11 (group 2a) and normal in 9
(group 2b). Seventeen patients had been treated effectively for at
least 1 year; nine (group 3a) had persistent
left ventricular
hypertrophy, and eight (group 3b) had no left ventricular hyper-
trophy before treatment. Left ventricular volumes and ejection
fraction were normal In all groups .
In hypertensive patients, angina pectoris, although fre-
quently ascribed to coronary atherosclerosis, may occur
with angiographically normal epicardial coronary
arteries
(1-3) .
It has been demonstrated that coronary vasodilator
reserve is reduced in hypertensive patients with left ventric-
ular hypertrophy and normal coronary arteries
(1,2) . More-
over, abnormally high coronary mierovasculature resistance
has been found in hypertensive patients without coronary
artery disease or left ventricular hypertrophy
(3) .
These
abnormalities in the coronary microcircutation may account
for angina and other signs suggestive of myocardial ischemia
(i .e . .
electrocardiographic (ECG] abnormalities [4), defects
on myocardial thallium-201 imaging [5) and structural alter-
ations of the myocardium 161) .
They may also contribute to
the increased morbidity and mortality observed in hyperten-
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Results
. Coronary reserve was moderately reduced in group 2b
(3.5 t 0.6 vs. 5.2 * 0
.8 in control subjects, p < 0.01) and
markedly diminished in groups 2a and 3a (2.5
t 0.5 and 2.7
t
0.4, respectively; all p < 0.001 vs . control subjects). In group 3b,
coronary reserve was comparable to that of control subjects
(5.1 t 1 .4).
Conclusions. The reduction in coronary reserve observed in
untreated hypertensive patients with normal myocardial mass
suggests that structural abnormalities of the coronary uticrovas-
culature may occur before left ventricular hypertrophy
. Treated
patients with normal mass before treatment had a coronary
reserve comparable to that of normotensive control subjects,
whereas normalization of arterial pressure with persistent left
ventricular hypertrophy was associated with a marked impair-
ment of coronary reserve.
(J Am Coll Cardiol 1993;22:514 20)
sive patients with left ventricular hypertrophy (7-9). With
regard to the effects of antihypertensive therapy on lets
ventricular hypertrophy and coronary reserve changes, ani-
mal studies have provided conflicting results (10-15), and
few data have been published to date on coronary reserve in
treated hypertensive patients (16,17) . In this study we ex-
amined whether coronary reserve may be different in un-
treated and treated hypertensive patients with regard to the
absence or persistence of let 'L ventricular hypertrophy (I8)
despite normalization of arterial blood pressure .
Methods
Patient selection . Thirty-seven hypertensive patients and
16 normotensive control subjects were referred for cardiac
catheterization because of a clinical suspicion of coronary
artery disease (symptoms suggestive of angina or single-
photon emission computed tomography stress thallium-201
scintigraphic findings suggesting myocardial ischemia)
. All
of the patients had normal epicardial coronary arteries and
normal left ventricular volumes and ejection fraction . Pa-
tients with cardiac arrhythmias, associated valvular heart
disease, diabetes mellitus, collagen disease or sarcoidosis
0735-1097193156.00
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were excluded . The study was approved by a local institu-
xional human research review committee, and informed
consent was obtained from each patient for the coronary
flow reserve study using an intracoronary Doppler catheter .
Echocardiographic assessment of left ventricular hypertro-
phy . Two-dimensional and M-mode echocardiography were
performed in each patient, using an Aloka model SSD-870
equipped with a phased-array 2 .5- or 3 .5-MHz transducer .
Left ventricular posterior wall thickness was measured, at
end diastole, according to the American Society of Echocar-
diography guidelines (19) on a two-dimensional guided
M-mode tracing cut through the chordae tendineae of the
mitral valve apparatus in the standard parasternal transverse
short-axis view . Normal left ventricular wall thickness was
defined as posterior wall thickness :S 10 mm and left ventric-
ular hypertrophy as posterior wall thickness ? 12 mm. Left
ventricular mass was calculated at end-diastole using the
Penn convention (20) . Patients with asymmetric septal hy-
pertrophy (septum/posterior wall thickness ratio > 1 .3) were
excluded. All patients had normal systolic function .
Control group . The control group (group I) comprised 16
subjects (14 men and 2 women with a mean age of 49 t
10 years) . All had arterial blood pressure values
< 140/90 mm Hg on several occasions . Two-dimensional and
M-mode echocardiographic findings were normal .
Hypertensive patients (groups 2 and 3) . These patients
had essential hypertension class I to 111 (21) . Three sets of
readings were obtained at least I week apart . On each
occasion, the mean of two readings was taken . Hypertension
was defined as blood pressure measurements
>1090 mm Hg. Patients in group 2 had sustained blood
pressure elevation > 160/90 mm Hg during a hospital stay
and had never been treated . They were classified into two
subgroups according to the presence (group 2a) or absence
(group 2b) of echocardiographic left ventriculac hypertro-
phy. Group 2a included I I patients (5 men and 6 women with
a mean age of 55 ± 9 years) . Results of the thallium scan
were negative in five patients and positive in six. Group 2b
comprised nine patients (six men and three women with a
mean age of 54 is S years). Of the eight patients in group 2b
who had a thallium scan, four had negative findings and four
had positive findings . Patients in group 3 had a history of
hypertension and developed chest discomfort or angina
while treated . They complied with an effective drug therapy
regimen for at least 1 year (arterial pressure < 150190 mm Hg
on several occasions). Group 3a comprised nine patients
(six men and three women with a mean age of 53 ± 6 years)
who had persistent left ventricular hypertrophy despite
normalization of blood pressure . They were treated with
angir'nsin-converting enzyme inhibitors (n = 5), beta-
adrenoreceptor blocking agents (n = 4), calcium channel
blocking agents (n = 6) or furosemide (n = 3), alone or in
combination. The average duration of treatment was 14
.6 t
2.0 months. Results of the thallium scan ware negative in five
patients and positive in four . Group 3b comprised eight
patients (four men and four women with a mean age of 53 ±
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9 years) without echocardiographic left ventricular hypertro-
phy before therapy . They were treated with angiotensin-
converting enzyme inhibitors (n = 4), beta-adrenoreceptor
blockers (n = 4), calcium channel blockers (n = 3), fu-
rosemide (n = 4) or peripherally acting antiadrenergic drugs
;r = 1), alone or in combination. The average duration of
treatment was 14 .4 t 2.1 months . Results of the thallium
scan were negative in five patients and positive in three .
Catheterization protocol. All patients were in the fasting
state for at least 12 h before the investigation . No premedi-
cation was administered, and 1% lidocaine was used for local
anesthesia . Treated hypertensive patients took their medi-
cations normally .
The Seldinger approach by way of the right femoral artery
was used to insert a 7F pigtail-tipped micromanometer
angiographic catheter (Cordis/Sentron v .o .f.) into the left
ventricle . Heart rate, aortic pressures and left ventricular
pressures were recorded and calculated by a catheterization
data analysis computer system (Hewlett-Packard model
5Y500 M) that performed on-line analysis on 9 beats for
averaging respiratory variations . Left ventricular angiogra-
phy (30 ml of ioxaglate meglumine) was performed in a 30°
tight anterior oblique projection, with simultaneous record-
ing of left ventricular pressure and exposed frame marker
(paper speed 100 mm/s) . Arteriograms of each coronary
artery were obtained in multiple projections and immediately
interpreted by two experienced observers who retained in
the study only patients with normal coronary a ies .
To evaluate coronary reserve, the following procedure
was carried out according to the method of Wilson and
White (22) . At least 15 min was allowed to elapse between
the end of coronary arteriography and subsequent measure-
ments . After intravenous administration of 5,000 U of hep-
arin sodium . an 8F coronary guiding catheter was positioned
in the left coronary artery and maximal epicardial coronary
vasodilation was obtained by intracoronary injection of
1 .5 mg of isosorbide dinitrate. A 3F 20-MHz coronary
Doppler catheter (Monorail Doppler 3, Schneider Europe
AG) connected to a single-channel 20-MHz pulsed Doppler
velocimeter (model MDV-20 Single Channel Velocimeter,
Millar Instruments, Inc .) was placed in the proximal left
anterior descending coronary artery . Catheter position was
adjusted to obtain an optimal audio signal and phasic tracing
of coronary blood flow velocity . Mean and phasic coronary
blood flow velocity (kilohertz shift), mean aortic pressure
through the guiding catheter withdrawn from the coronary
ostium into the aorta and the ECG were continuously
recorded under baseline conditions and after induction of
hyperemia by injection of 12 mg of papaverine hydrochloride
into the left coronary artery through the proximal lumen of
the coronary Doppler catheter (8 mg of papaverine/ml
of
0.9% saline solution) .
Ventriculographie analysis . Left ventricular end-diastolic
and end-systolic volumes were calculated using the area-
length method (23) .
Left ventricular wall thickness (mm) was
measured at end-diastole at the equator of the left ventricle
.
Actual wall thickness at end-diastole (hED) was calculated
after correction for X-ray image distortion by filming a
calibrated grid at the assumed location of the left ventricle .
The ratio of the true length on the grid to the corresponding
measured length on the film was the correction factor (CF) .
The actual thickness was obtained by the following equation :
hED (mm) = hm (mm) x CF.
Left ventricular mass was calculated by the method of
Rackley et al . (24) . The left ventricular wall volume was then
assumed to be constant, and its value was used to calculate
wall thickness on each systolic frame .
Peak systolic equatorial wall stress was calculated using
the equation of Falsetti et al . (25) for an ellipsoid geometry of
the left ventricle . Each value of left ventricular volume after
aortic valve opening was used to calculate ventricular ra-
dius, wall thickness and wall stress using the corresponding
pressure until the peak value of peak systolic equatorial wall
stress was obtained,
Coronary vtlmodllator reserve . Coronary flow reserve was
calculated as the ratio of peak blood flow velocity (maximal
kilohertz shift after papaverine) and rest blood flow velocity
(22) (average of two successive measurements, of which the
second was performed after return to baseline coronary flow
velocity). To evaluate the coronary resistance reserve, a
minimal coronary vascular resistance index was calculated
as the Mean aortic pressure at peak flow velocity/Peak flow
velocity divided by Mean aortic pressure at rest flow veloc-
ity)Rest flow velocity (22) .
Sid noalysls. Results are expressed as meats value
* SD. Comparisons between groups were performed using
one-way analysis of variance . When authorized, compari-
sons between two groups were performed using a two-tailed
unpaired t test
. Bonferroni's corrections were performed to
adjust the significance level according to the comparison
number
. Statistical difference was assumed if the null hy-
pothesis could be rejected at the 0
.05 probability level .
'p < 0.001 . *p < 0 .05. tp < 0.01 (data of groups 2a, 2b, 3a, and 3b are compared with data orgroup I ).
Group I = normotensive subjects
: group 2 = untreated
hypertensive patients with (group 2a) or without (group 2b) left ventricular hypertrophy ; group 3 = treated patients with (group 3a) or without (group 3b) left
ventricular hypertrophy. DAP
-
diastolic aortic pressure : EF ® ejection fraction ; HR
- heart rate : LVEDP = left ventricular end-diastolic pressure ; LVEDV
- left ventricular end-diastolic volume ; LVESV - left ventricular end-systolic volume ; LVM
-
left ventricular mass ; LVSP
-
left ventricular systolic pressure :
MAP - mean au+tie pressure ;
Rate-pressure product - Heart rate x Systolic blood pressure in mm Hl/min x 10 2 .
Results
Hemodynamic variables. Hemodynamic data are summa-
rized in Table 1 . There were no significant differences in age
and heart rate among the five groups of patients . In untreated
hypertensive patients (groups 2a and 2b), left ventricular
systolic pressure, diastolic and mean aortic pressures and
double product were significantly higher than in c,)ntrol
patients . Left ventricular end-diastolic pressure was also
increased compared with control subjects and exceeded
16 mm Hg in four patients with left ventricular hypertrophy
and three patients without left ventricular hypertrophy . In
treated hypertensive patients with left ventricular hypertro-
phy (group 3a), only left ventricular end-diastolic pressure
was mildly but significantly elevated. All of the other vari-
ables were comparable to those of control subjects . In group
3a, the highest left ventricular end-diastolic pressure was
14 mm Hg. In treated hypertensive patients without left
ventricular hypertrophy (group 3b), left ventricular systolic
pressure was higher than in the control group but neverthe-
less within the normal range . Diastolic and mean aortic
blood pressures, as well as left ventricular end-diastolic
pressure and double product, were comparable to those of
the control group .
Anglographic variables. Left ventricular angiography ev-
idenced comparable values for end-diastolic and end-systolic
volumes and ejection fraction in the five groups of patients
(Table 1). In control subjects, maximal end-diastolic wall
thickness was 9.2 mm, and maximal left ventricular mass
index was 98 g/mx. Groups 2a and 3a (hypertension and left
ventricular hypertrophy) had, by select .i, higher values for
left ventricular wall thickness and mass index compared with
those of control subjects (Fig . 1). These elevations were
comparable in the two groups . End-diastolic wall thickness
ranged from 10 .8 to 18 .6 mm in group 2a and from 10.4 to
13.4 mm in group 3a
. Indexed left ventricular myocardial
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Table 1
. Hemodynamic Variables at Rest in the Notmotensive Group and in the Four Groups of Hypertensive Patients
Group I
(n = 16)
Group 2a
(n=11)
Group 2b
(n=9)
Group 3a
(n=9)
Group 3b
(n=8)
Age ( yr) 49 ±10 55±9 54±g
53±6 53±9
HR (beats/min) 76 ± 6
80 ± 12 75 ± 7 72±±9 72±8
LVSP (mm Hg)
124 ± 8 184 ± 16' 172 ± 14' 130 ± 16 138 ± 9t
DAP (mm Hg) 78 ± 7 103 ± 9' 103 ± 9' 83t 13 78±6
MAP (mm Flg) 97 ± 8 132 ± 9*
132 t 11 0 105 ± 16 99 ± 8
LVEDP (mm Hg) 9 ± 2
15±5#
15
± 3* 11±2* 10±3
LVEDV (ml) 79 ± ID 80 ± 14 87±9 77±9 85±15
LVESV (ml)
26 ± 7 26 t9 32±8 29±7 24±10
EF (%)
67 ± 7 69±8 64±7 63±9 71±10
Rate'pressure product 94 19 147 ± 17*
147 t 17' 94± 13 98±9
Echocardiographic LVM index (grm) 88 :t 12 153 ± 18* 93 ± 12 146 ± 14* 94 ± 15
JACC Vol . 22, No. 2
August 1993 :514-20
N
to
a
•
	
150
50
d
J
0
500
•
400
E
u
U
Z300
• of
•
200
to
~ y
N
too
200
NS
00
.001
NNIN
00.001
p
61 62a 621, 63a 63b
Figure 1 . Angiographic data . G I = control group ; G2a = untreated
hypertensive patients with left ventricular hypertrophy . G2b
untreated hypertensive patients without left ventricular hypertro-
phy . G3a = treated patients with left ventricular hypertrophy .
Gab = treated patients without left ventricular hypertrophy . Data
for each hypertensive group are compared with those in the control
group .
mass ranged from 120 to 202 glm2 in group 2a and from 120
to 160 g/m2 in group 3a . In no case did angiographic data
show that echocardiographic data had led to misclassifica-
tion in a normal or high left ventricular mass group at
inclusion. In addition, in every patient in groups 2a and 3a,
the left ventricular mass index was >4 SD greater than the
mean value in the control group . In the latter group, values
were consistent with previously published angiographically
detaunined values (24) . In groups 2b and 3b (hypertension
without left ventricular hypertrophy), left ventricular wall
thickness and left ventricular mass were comparable to those
of control subjects (Fig . 1). In untreated patients with
increased left ventricular mass (group 2a), the peak systolic
wall stress was within the normal range. In contrast, this
variable was increased in the untreated hypertensive group
with normal left ventricular mass (group 2b) compared with
the control value. The persistence of increased wall thick-
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Figure 2 . Plot of coronary flow and resistance reserve in control
subjects and hypertensive patients . The lower limit of normal
coronary flow reserve (peak/rest flow velocity = 3 .6) and the upper
limit of normal coronary resistance reserve (minimal coronary
vascular resistance index = 0.24) are depicted by the dotted line .
Abbreviations as in Figure I .
0• .5
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.4
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•
.0
ness despite normalization of arterial blood pressure resulted
in a lower than normal peak systolic wall stress in group 3a
(Fig. 1). In treated hypertensive patients without left ven-
tricular hypertrophy (group 3b), the peak systolic wall stress
was within the normal range .
Coronary flow reserve (Fig . 2). Control subjects had a
mean coronary flow reserve of 5 .2 ± 0.8. Normal flow
reserve was defined as a mean coronary flow velocity after
papaverine a:3.6 times the baseline flow velocity . This value
corresponded to the mean value - 2 SID of our control group
and was comparable to the lower limit of normal coronary
vasodilator reserve reported by Wilson and White (22) and
McGinn et al . (26) (i .e., 3.5 and 3 .7, respectively). In all
untreated patients with elevated left ventricular mass, the
coronary flow reserve was markedly reduced In this group
(group 2a), values ranged from 1 .7 to 3 .2 (2
.5 ± 0.5) .
Coronary flow reserve was moderately reduced in untreated
hypertensive patients with normal left ventricular mass
(group 2b), with values ranging from 2 .7 to 4 .6 (3 .5 *-
0.6) .
Coronary flow reserve was reduced in five patients ., equal to
3.6 in one patient and normal in three patients
. In this group
of untreated patients without left ventricular hypertrophy,
mean coronary flow re erye was sig!t+'flrantly higher than in
the untreated patient with increased left ventricular mass
.
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In treated patients with persistent left ventricular hypertro-
phy, the reduction in coronary reserve was similar to that
observed in untreated patients with left ventricular hyper-
trophy, with values ranging from 2 .2 to 3 .3 (2 .7 ± 0
.4) . In
treated hypertensive patients with normal left ventricular
mass, coronary flow reserve was comparable to that of
control subjects and significantly higher than in untreated
patients with normal left ventricular mass . It was also
significantly higher than in treated patients with persistent
increased left ventricular mass. All values were >3
.6, with
the exception of those of one man who had a coronary flow
reserve of 3 .5 (5 .1 ± 1 .4) .
Minimal coronary vascular resistance index (Fig. 2) . In
control subjects the minimal coronary vascular resistance
index was 0 .18 ± 0 .03. The upper limit of the minimal
coronary vascular resistance index was defined as the mean
value + 2 SD in our control groups (i .e ., 0.24). Coronary
resistance reserve data were consistent with flow reserve
data. The minimal coronary vascular resistance index was
markedly elevated in all of the untreated patients with
increased left ventricular mass. In the untreated patients
with normal left ventricular mass, all those who had a
coronary flow reserve 2t3 .6 also had a minimal coronary
vascular resistance index s0.24, except one whose index
was 0.25. Those with a coronary flow reserve <3 .6 had a
minimal coronary vascular resistance index >0 .24. In
treated patients with persistent increased left ventricular
mass, alterations in resistance were as marked as in un-
treated patients with left ventricular hypertrophy . In treated
hypertensive patients with normal left ventricular mass,
minimal coronary vascular resistance index was not signifi-
cantly different from that of control subjects and was signif-
icantly lower than in untreated patients with normal cardiac
mass; however, two patients had values equal to 0 .25 and
0.26 .
Discussion
Coronary row" in untreated hypertensive patients with-
ent left ventricular hypertrophy. Angina can occur in hyper-
tensive patients, even in the absence of epicardial coronary
artery disease and left ventricular hypertrophy (3). Abnor
mal coronary resistance at rest and during atrial pacing has
been evidenced in hypertensive patients without left ventric-
ular hypertrophy (3). The present study is the first showing a
moderate but significant decrease in coronary vasodilator
reserve in untreated hypertensive patients with angiograph-
ically normal coronary arteries and normal left ventricular
mass
. Although this group was heterogeneous and included
patients with normal or reduced coronary reserve, mean
coronary vasodilator reserve was significantly higher than in
the untreated group of hypertensive patients with increased
left ventricular mass .
ve therapy and coronary reserve to patients
withont left ventrkolar hypertrophy
. For ethical reasons, we
were not ably to investigate, in the same patients, whether an
JACC Vol . 22, No. 2
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abnormal coronary reserve can be improved or even normal-
ized after antihypertensive therapy . In treated patients with
normal cardiac mass before treatment, coronary reserve was
within the normal range; it seems highly unlikely that all of
these patients had a normal coronary reserve before therapy .
Because coronary vasodilator reserve in these patients was
comparable to that in the control group, we might hypothe-
size that coronary reserve was improved by antihyperten-
sive therapy .
itntihypertensive therapy and coronary reserve in patients
with left ventricular hypertrophy. In patients with persistent
elevated left ventricular mass despite normalization of blood
pressure, coronary vasodilator reserve was markedly re-
duced. It was significantly lower than in treated patients with
normal cardiac mass and as markedly reduced as in un-
treated patients with left ventricular hypertrophy . Thus,
normalization of blood pressure was not sufficient to im-
prove coronary reserve when left ventricular hypertrophy
persisted. The effects of medications on coronary reserve
should not have significantly affected our results . Indeed,
previous work demonstrated that beta-adrenoreceptor
blockers (26) or calcium channel blockers (27,28) did not
significantly alter coronary reserve and that enalaprilat
mildly reduced coronary resistance at rest (29) . Although our
study did not address the mechanisms underlying the reduc-
tion in coronary reserve, some discussion of this point is
important to the understanding of the potential reversibility
of coronary circulation abnormalities under antihypertensive
therapy .
Factors that may impair coronary reserve in hypertensive
patients. In arterial hypertension, basal coronary flow is
increased because of increased myocardial oxygen demand ;
however, if the total maximal area of the microcirculation is
normal, maximal flow should increase in proportion to basal
flow because coronary perfusion pressure is increased, and
the coronary reserve should be normal (30). Two mecha-
nisms may be responsible for a reduction in coronary vas-
cular reserve . The first is limitation of maximal flow second-
ary to a reduction in the total maximal cross-sectional area of
the microcirculation (30), and the second involves increased
flow at rest not related to the elevation in arterial pressure .
Several factors may contribute to a reduction in the total
maximal cross-sectional area of the coronary microvascula-
ture; 1) Structural abnormalities in intramyocardial coronary
arteries have been evidenced in autopsy studies of hyperten-
sive patients with left ventricular hypertrophy (31) . More-
over, medial hypertrophy of intramural coronary arteries is
not directly related to left ventricular hypertrophy (32) .
2) Rarefaction of resistance vessels may have occurred (33) .
3) Extravascular systolic compression may also limit total
maximal coronary flow when left ventricular wall stress is
increased; however, this is unh.kely because -90% of the
caronaiy flow occurs during diastole . Conversely, augmen-
tation of diastolic myocardial tissue pressure may also
preclude maximal increase in microvascular diameter (2),
and increased left ventricular preload (pulmonary wedge
.IACC Vol . 22 . No . 2
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pressure equal to 16 mm fig) has been shown to decrease
coronary flow reserve by x24% (34) . Thus, the mild eleva-
tion in left ventricular end-diastolic pressure that we ob-
served in untreated patients may have contributed to a small
degree to the decrease in coronary reserve .
The possibility that increased baseline flow due to accel-
eration of heart rate occurred in our study can be ruled out
because heart rates were similar in hypertensive patients and
control subjects . The mechanical cost of compression of
interstitial ubrosis, an alteration reported in hypertensive
human hearts with left ventricular hypertrophy (31,35), may
result in an increase in oxygen demand at rest and in baseline
coronary flow, even after normalization of arterial pressure .
Potential role of antihypertensive therapy . These mecha-
nisms underlying a reduction in coronary reserve have
implications for the goal of antihypertensive therapy, which
should not only normalize blood pressure but also reverse
left ventricular hypertrophy, myocardial fibrosis and struc-
tural changes in intramyocardial arteries . Although most
antihypertensive agents have demonstrated their efficacy in
decreasing myocardial mass (36-38), data on their effects on
collagen content and structure of coronary arteries are still
conflicting. In some animal studies, myocardial fibrosis
persisted despite regression of left ventricular hypertrophy
(10,11), whereas it resolved in others (13,14) . In another
study reported by Brilla et al . (15), coronary vasodilator
reserve was normalized only when blood pressure, myocar-
dial mass and medial wall thickness of intramyocardial
arteries were normalized . These results are in conflict with
those of Anderson et al . (12), who demonstrated an improve-
ment in coronary reserve and coronary structural alterations
with hydralazine, which normalized blood pressure but did
not cause regression of myocardial hypertrophy. These
conflicting results may be due to differences in the regulation
of myocardial hypertrophy and structural abnormalities of
coronary microcirculation . In humans, Vtr„t et al. (17)
reported an improvement in coronary reserve after long-
term angiotensin-converting enzyme inhibitor therapy . This
improvement was observed in hypertensive patients with
mild left ventricular hypertrophy and seemed to be due to
effects of therapy on coronary microcirculation because
reversal of left ventricular hypertrophy was not pronounced .
In our study, treated patients with persistent left ventricular
hypertrophy had a marked reduction in coronary reserve .
Limitations of the study. Coronary reserve was not eval-
uated before and after treatment in the same patients be-
cause, for ethical reasons, it was not possible to repeat the
investigative procedures in patients who were included
before therapy . With regard to patients with a normal
cardiac mass who were included after initiation of treatment,
we selected those whose cardiac mass was normal before
treatment to obtain a homogeneous group and to allow
comparison with the group of untreated patients with normal
cardiac mass .
Coronary reserve was evaluated by the maximal/basal
coronary flow ratio estimated by the peakirest flow velocity
and a minimal coronary vascular resistance index, which
takes into account aortic pressure alterations induced by
intracoronary papav,.rive (22) . This technique has been
extensively validated but it does not measure absolute flows
and does not allow the determination of whether the reduc-
tion in coronary reserve is due to elevation of rest flow or
reduction in maximal flow .
The role of antihypertensive therapy in coronary reserve
has been studied in the aggregate.; however, various antihy-
pertensive drug classes or even different drugs in the same
class may have different effects on regression of myocardial
fibrosis (11,12) or reversal of abnormalities in intramyocar-
dial arteries. The groups of patients that we studied were too
small to allow a study of correlations between the antihyper-
tensive regimens used and coronary reserve . Moreover,
most of our patients were -eceiving two-drug therapy .
The persistence of left ventricular hypertrophy in group
3a cannot be attributed to either abnormal arterial pressure
or inadequate duration of therapy because the efficacy of
antihypertensive therapy was documented for at least 12
months; furthermore, this persistence cannot be attributed
to the use of a class of hypertensive agents that are not
appropriate for inducing regression of left ventricular hyper-
trophy .
Conclusions. A moderate reduction in coronary reserve
was observed in untreated hypertensive patients with normal
left ventricular mass. The coronary reserve of treated pa-
tients with normal cardiac mass before therapy was compa-
rable to that in the normotensive group. In contrast, treated
patients with persistent increased left ventricular mass de-
spite normalization of blood pressure showed a marked
reduction in coronary reserve . Further investigations using
noninvasive methods allowing actual coronary blood flow
measurements in the same patients before and after therapy
should provide new insight into the specific effects of differ-
ent antihypertensive medications on coronary reserve .
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